South Dakota
How Association for Molecular Pathology v. Myriad Genetics, Inc. applies in South Dakota: state-specific rules, key cases, and bar exam notes for Intellectual Property (Patent Law).
South Dakota adheres to federal patent law principles, particularly in biotechnology and life sciences. However, local interpretations can influence the application of patent eligibility standards.
In South Dakota, as in federal law, naturally occurring genes are not patentable, but cDNA and any useful inventions derived from genetic research may be eligible for patent protection.
Held that inventions derived from natural products must demonstrate distinct, non-obvious utility to qualify for patent protection.
Found that patents must comply with both state and federal regulations regarding the patentability of biological inventions.
South Dakota's approach aligns closely with the federal standard established by the Myriad case, which prohibits the patenting of naturally occurring DNA. Nevertheless, state courts have more leeway to interpret the applicability of state exemptive statutes for biotech patents.
Understanding the implications of Myriad is crucial for South Dakota bar exam takers, particularly in relation to patent eligibility for genetic materials.